Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to find how Elevance Health’s medical loss ratio or Medicaid membership changed quarter-by-quarter? The company’s disclosures run hundreds of pages and detail complex Blue Cross Blue Shield licensing, state risk corridors, and pharmacy benefit trends. Elevance Health SEC filings explained simply can save professionals hours—especially when you need Elevance Health insider trading Form 4 transactions right before an earnings call.
Stock Titan’s platform delivers just that. Our AI reads every Elevance Health quarterly earnings report 10-Q filing, flags deviations, and produces concise narratives. Need Elevance Health Form 4 insider transactions real-time? You’ll get alerts within seconds. Each document page is paired with a side-by-side Elevance Health earnings report filing analysis, making understanding Elevance Health SEC documents with AI straightforward. We also surface:
- Elevance Health annual report 10-K simplified into key metrics
- Elevance Health proxy statement executive compensation distilled to pay-for-performance tables
- Elevance Health 8-K material events explained so you grasp market-moving news instantly
Whether you track Commercial & Specialty Business growth, scrutinize Government Business risk, or monitor Elevance Health executive stock transactions Form 4 for sentiment shifts, our coverage stays current with EDGAR in real time. Investors use these insights to compare segment margins, watch medical loss ratios, and anticipate regulatory impacts—without wading through dense accounting language. Access every filing, AI summary, and historical trend in one place, and make faster, better-informed decisions.
Erin M. Wessling, Executive Vice President and Chief Legal Officer of Elevance Health, acquired equity awards in the issuer. The Form 4 reports receipt of 931 restricted stock units at no cash cost and an employee stock option to purchase 3,541 shares at an exercise price of $322.33. The RSUs vest in three annual tranches (310, 310 and 311 shares) and the option vests in three annual installments (1,180; 1,180; 1,181 shares) beginning one year after grant, with the option exercisable through its stated expiration. The reported holdings after the transactions are 5,172 shares and 3,541 option shares, each held directly.
Craig Ryan R, EVP & Chief HR Officer of Elevance Health, Inc. (ELV), reported equity awards and an option grant on 09/02/2025. He was awarded 970 restricted share units (RSUs) with a $0 purchase price and now beneficially owns 5,353 shares. He also received an employee stock option with an exercise price of $322.33 for 3,690 shares, exercisable in three annual installments beginning 09/02/2026 and expiring 09/02/2035, leaving 3,690 underlying shares from the option. The RSUs vest in annual installments of 323, 323, and 324 shares on 9/2/2026, 9/2/2027 and 9/2/2028 respectively.
Elevance Health management expects to reaffirm full-year 2025 shareholders' earnings guidance of approximately $24.10 per diluted share, which includes about $5.90 per diluted share of net unfavorable items. Excluding those items, the Company expects adjusted shareholders' earnings of approximately $30.00 per diluted share.
The company also plans to reaffirm a full-year 2025 benefit expense ratio guidance of approximately 90.0%. Management cautions these expectations reflect current views of market, operational, regulatory and claim-cost assumptions and may change, and the filing includes standard forward-looking statement disclosures.
Susan D. DeVore, a director of Elevance Health, reported purchases of common stock totaling 1,200 shares on 08/19/2025 at a weighted average price of $312.15 per share. After these purchases she beneficially owned 3,502 shares directly. The filing specifies the purchases were executed in multiple trades at prices between $312.06 and $312.19, and the weighted average price is disclosed. The Form 4 was signed by an attorney-in-fact for the reporting person.
FAQ
What is the current stock price of Elevance Health (ELV)?
What is the market cap of Elevance Health (ELV)?
